ACAM2000® smallpox vaccine

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smallpox

Conditions

Smallpox

Trial Timeline

Dec 1, 2008 → Dec 31, 2017

About ACAM2000® smallpox vaccine

ACAM2000® smallpox vaccine is a pre-clinical stage product being developed by Emergent BioSolutions for Smallpox. The current trial status is completed. This product is registered under clinical trial identifier NCT00927719. Target conditions include Smallpox.

Hype Score Breakdown

Clinical
5
Activity
2
Company
2
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00927719Pre-clinicalCompleted

Competing Products

20 competing products in Smallpox

See all competitors
ProductCompanyStageHype Score
Smallpox vaccine, LISTER strain, from chick embryo cellsSanofiPhase 2
51
MVA (smallpox vaccine)SanofiPhase 1
32
ACAM3000 MVA VaccineSanofiPhase 1
32
MVA Smallpox vaccine + PlaceboSanofiPhase 2
51
ACAM1000 + vaccinia virus (calf lymph) smallpox vaccine: DryvaxSanofiPhase 2
51
IMVAMUNE (MVA-BN)Bavarian NordicPhase 2
49
MVA-BNBavarian NordicPhase 1
30
IMVAMUNE®Bavarian NordicPhase 2
49
LF formulation of IMVAMUNE® + FD formulation of IMVAMUNE®Bavarian NordicPhase 2
49
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
49
FD MVA-BNBavarian NordicPhase 3
74
IMVAMUNE®Bavarian NordicPhase 3
74
IMVAMUNE + IMVAMUNEBavarian NordicPhase 2
49
MVA-BN® (IMVAMUNE) + PlaceboBavarian NordicPhase 2
49
Elstree-BNBavarian NordicPhase 1
30
ACAM2000Emergent BioSolutionsPhase 3
69
VIGIVEmergent BioSolutionsPre-clinical
15
BrincidofovirEmergent BioSolutionsPhase 1
25
Vaccination with ACAM2000Emergent BioSolutionsApproved
77
ACAM2000 Smallpox Vaccine + Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®Emergent BioSolutionsPhase 2
44